Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system.
作者信息
Accurso Vincenzo, Santoro Marco, Mancuso Salvatrice, Napolitano Marisante, Di Piazza Florinda, Russo Antonio, Siragusa Sergio Mario
机构信息
Divisione di Ematologia A.O.U.P. Palermo, Palermo, Italy.
Laboratorio di Biologia Molecolare oncologia A.U.O.P Palermo, Palermo, Italy.
出版信息
Drugs Context. 2019 Mar 4;8:212569. doi: 10.7573/dic.212569. eCollection 2019.
Abstract
摘要
相似文献
1
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system.
Drugs Context. 2019 Mar 4;8:212569. doi: 10.7573/dic.212569. eCollection 2019.
2
The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
Cancer. 2016 Mar 1;122(5):681-92. doi: 10.1002/cncr.29842. Epub 2015 Dec 30.
3
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
Exp Hematol Oncol. 2015 Sep 15;4:26. doi: 10.1186/s40164-015-0021-2. eCollection 2015.
4
Prognostic risk models for transplant decision-making in myelofibrosis.
Ann Hematol. 2018 May;97(5):813-820. doi: 10.1007/s00277-018-3240-x. Epub 2018 Jan 25.
5
Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience.
Indian J Pathol Microbiol. 2015 Apr-Jun;58(2):187-91. doi: 10.4103/0377-4929.155311.
6
Prognosis of Primary Myelofibrosis in the Genomic Era.
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S105-13. doi: 10.1016/j.clml.2016.02.031.
7
Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.
Adv Hematol. 2015;2015:848473. doi: 10.1155/2015/848473. Epub 2015 Nov 9.
8
Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.
Eur J Haematol. 2010 Feb 1;84(2):105-8. doi: 10.1111/j.1600-0609.2009.01373.x. Epub 2009 Nov 6.
9
Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.
Intern Med. 2018 May 1;57(9):1297-1300. doi: 10.2169/internalmedicine.9165-17. Epub 2017 Dec 27.
10
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.
Ther Clin Risk Manag. 2017 Feb 13;13:169-177. doi: 10.2147/TCRM.S121683. eCollection 2017.
引用本文的文献
1
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
Acta Haematol. 2022;145(4):448-453. doi: 10.1159/000520440. Epub 2022 Jan 10.
本文引用的文献
1
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.
2
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z.
3
Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Am J Hematol. 2016 Dec;91(12):1262-1271. doi: 10.1002/ajh.24592.
4
The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances.
Blood Rev. 2016 Nov;30(6):453-459. doi: 10.1016/j.blre.2016.06.001. Epub 2016 Jun 11.
5
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
Haematologica. 2016 Sep;101(9):1065-73. doi: 10.3324/haematol.2016.143677. Epub 2016 May 31.
6
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
Leukemia. 2016 Aug;30(8):1701-7. doi: 10.1038/leu.2016.148. Epub 2016 May 23.
7
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.
8
Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.
Am J Hematol. 2014 Mar;89(3):344-6. doi: 10.1002/ajh.23637.
9
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Blood. 2013 Dec 12;122(25):4047-53. doi: 10.1182/blood-2013-02-485888. Epub 2013 Oct 30.
10
U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype.
Leukemia. 2014 Feb;28(2):431-3. doi: 10.1038/leu.2013.286. Epub 2013 Oct 7.
Zotero 插件